Effect of mandibular advancement device treatment on HIF‑1α, EPO and VEGF in the myocardium of obstructive sleep apnea–hypopnea syndrome rabbits
Effect of mandibular advancement device treatment on HIF‑1α, EPO and VEGF in the myocardium of obstructive sleep apnea–hypopnea syndrome rabbits
复制标题
下颌前移装置治疗对阻塞性睡眠呼吸暂停低通气综合征兔心肌HIFα1α、EPO和VEGF的影响
DOI：
10.1038/s41598-020-70238-0
复制
发表时间：
2020
影响因子：
4.6
通讯作者：
卢海燕
中科院分区：
文献类型：
--
作者：
朱德超;康文静;张士珑;乔星;刘春艳;卢海燕
本研究旨在探讨下颌推进器治疗阻塞性睡眠呼吸暂停低通气综合征对心肌组织中缺氧诱导因子-1α、促红细胞生成素和血管内皮生长因子的影响。用新西兰大白兔制作OSAHS和MAD模型。动物仰卧位进行上呼吸道锥束计算机体层摄影(CBCT)和多导睡眠图(PSG)记录。每天诱导动物仰卧睡眠4~6h，连续观察8周。取3组大鼠心肌组织，检测缺氧诱导因子-1α、促红细胞生成素和血管内皮生长因子的表达。结果显示，阻塞性睡眠呼吸暂停低通气综合征组缺氧诱导因子-1α、促红细胞生成素和血管内皮生长因子的表达明显高于非阻塞性睡眠呼吸暂停综合征组和对照组。MAD治疗可显著下调阻塞性睡眠呼吸暂停低氧大鼠肺组织中缺氧诱导因子-1α、促红细胞生成素和血管内皮生长因子的表达。结论：MAD治疗可显著下调阻塞性睡眠呼吸暂停低通气综合征兔心肌组织中缺氧诱导因子-1α、促红细胞生成素和血管内皮生长因子的表达，改善心功能。
The aim of this study was to investigate the effects of mandibular advancement device (MAD) therapy for obstructive sleep apnea–hypopnea syndrome (OSAHS) on hypoxia-inducible factor-1α (HIF-1α), erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in myocardial tissue. New Zealand rabbits were used to develop OSAHS and MAD models. Cone beam computed tomography (CBCT) of the upper airway and polysomnography (PSG) recordings were performed with the animals in the supine position. All of the animals were induced to sleep in a supine position for 4–6 h each day and were observed continuously for 8 weeks. The myocardial tissue of the three groups was dissected to measure the expression of HIF-1α, EPO and VEGF. The results showed that there was higher expression of HIF-1α, EPO and VEGF in the OSAHS group than those in the MAD and control groups. MAD treatment significantly downregulated the expression of HIF-1α, EPO and VEGF in the OSAHS animals. We concluded that MAD treatment could significantly downregulate the increased expression of HIF-1α, EPO and VEGF in OSAHS rabbits, improving their myocardial function.